Please login to the form below

Not currently logged in
Email:
Password:

EGFR inhibitor

This page shows the latest EGFR inhibitor news and features for those working in and with pharma, biotech and healthcare.

Merck gets first approval for MET inhibitor tepotinib in Japan

Merck gets first approval for MET inhibitor tepotinib in Japan

Other rivals include AstraZeneca with small-molecule candidate savolitinib in mid-stage testing for NSCLC patients who have progressed after treatment with its EGFR inhibitor Tagrisso (osimertinib) as well as in ... combination. MET is known as a

Latest news

More from news
Approximately 1 fully matching, plus 69 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    EGFR-TK) inhibitor, which has so far been approved in non-small cell lung cancer, albeit after a much-delayed, stop-start regulatory journey. ... If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics